Lenzilumab

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].

Product Specifications

CAS Number

[1229575-09-0]

Product Name Alternative

KB 003

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lenzilumab.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[Lenzilumab]

Molecular Weight

(145.72 kDa)

References & Citations

[1]Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133 (7) :697-709.|[2]Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95 (11) :2382-2394.